RBC Capital Maintains Outperform on Maravai LifeSciences, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Conor McNamara maintains an Outperform rating on Maravai LifeSciences (NASDAQ:MRVI) and raises the price target from $12 to $14.
February 23, 2024 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Conor McNamara maintains an Outperform rating on Maravai LifeSciences and raises the price target from $12 to $14.
The upgrade in price target by a reputable analyst like Conor McNamara from RBC Capital is a strong positive signal for Maravai LifeSciences. It suggests a bullish outlook on the company's future performance and potential for stock price appreciation. Such analyst actions often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100